Sunitinib malate

By Izzedine Hassane   Buhaescu Irina   Rixe Olivier   Deray Gilbert  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 3, 2007-08 ,pp. : 357-364

Springer Publishing Company

Access to resources Recommend Favorite

Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient

By Medioni Jacques   Cojocarasu Oana   Banu Eugeniu   Cassar-Queudeville Alexia   Halimi Philippe   Oudard Stéphane  

Targeted Oncology, Vol. 2, Iss. 3, 2007-07 ,pp. : 193-195

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations

By                    

Oncology Letters, Vol. 4, Iss. 3, 2012-01 ,pp. : 501-504

Spandidos Publications

Access to resources Recommend Favorite

Long-Term Response and Postsurgical Complete Remissions After Treatment With Sunitinib Malate, an Oral Multitargeted Receptor Tyrosine Kinase Inhibitor, in Patients With Metastatic Renal Cell Carcinoma

By Ayllon Jorge   Beuselinck Benoit   Morel Alexandre   Barrascout Eduardo   Medioni Jacques   Scotte Florian   Oudard Stééphane  

Cancer Investigation, Vol. 29, Iss. 4, 2011-04 ,pp. : 282-285

Informa Healthcare

Access to resources Recommend Favorite

Changes in resting energy expenditure (REE) as a function of tumor response to sunitinib in a cachexic patient with a metastatic endocrine tumor of the pancreas

By Zoheir Yasmina   Leroux Catherine   Picot Denis   Boucher Eveline   Audrain Odile   Raoul Jean-Luc  

Acta Oncologica, Vol. 49, Iss. 8, 2010-11 ,pp. : 1390-1391

Informa Healthcare

Access to resources Recommend Favorite